Drug Prices
The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs.
AHA applauds the U.S. House of Representatives for considering the Strengthening
Health Care and Lowering Prescription Drug Costs Act.
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as all of their previous attempts.
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market.
The Centers for Medicare & Medicaid Services (CMS) today released a final rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products for consumers.
The House Energy and Commerce Subcommittee on Health today held a hearing examining the increasing cost of prescription drugs in the Medicare program and ways to improve coverage and reduce costs for seniors.
AHA letter to Senator Richard J. Durbin expressing support for legislation, S. 551, the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act.
The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit managers.
The House Energy and Commerce Subcommittee on Oversight and Investigations today held the second part of a hearing on the rising cost of insulin, which featured witnesses from the nation’s three insulin manufacturers as well as three pharmacy benefit managers.